[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: Preliminary results

Francesco Pasqualetti, Marco Panichi, Aldo Sainato, Fabrizio Matteucci, Luca Galli, Paola Cocuzza, Patrizia Ferrazza, Gabriele Coraggio, Giuseppe Pasqualetti, Lisa Derosa, Martina Sollini, Lorenzo Mannelli, Simona Ortori, Fabio Monzani, Sergio Ricci, Carlo Greco, Maria Grazia Fabrini, Paola Anna Erba

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). Methods: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [18F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [18F]FMCHPET/CT. Results: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3-40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20-62.14 months). No grade 3 or 4 toxicity was recorded. Conclusions: Repeated salvage [18F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa.

Original languageEnglish
Article number9
JournalRadiation Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 22 2016

Fingerprint

Radiosurgery
Prostatic Neoplasms
Decision Making
Therapeutics
fluoromethylcholine
Disease Progression
Neoplasm Metastasis
Survival

Keywords

  • Choline PET/CT
  • Oligometastatic patients
  • Recurrent prostate cancer
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients : Preliminary results. / Pasqualetti, Francesco; Panichi, Marco; Sainato, Aldo; Matteucci, Fabrizio; Galli, Luca; Cocuzza, Paola; Ferrazza, Patrizia; Coraggio, Gabriele; Pasqualetti, Giuseppe; Derosa, Lisa; Sollini, Martina; Mannelli, Lorenzo; Ortori, Simona; Monzani, Fabio; Ricci, Sergio; Greco, Carlo; Fabrini, Maria Grazia; Erba, Paola Anna.

In: Radiation Oncology, Vol. 11, No. 1, 9, 22.01.2016.

Research output: Contribution to journalArticle

Pasqualetti, F, Panichi, M, Sainato, A, Matteucci, F, Galli, L, Cocuzza, P, Ferrazza, P, Coraggio, G, Pasqualetti, G, Derosa, L, Sollini, M, Mannelli, L, Ortori, S, Monzani, F, Ricci, S, Greco, C, Fabrini, MG & Erba, PA 2016, '[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: Preliminary results', Radiation Oncology, vol. 11, no. 1, 9. https://doi.org/10.1186/s13014-016-0586-x
Pasqualetti, Francesco ; Panichi, Marco ; Sainato, Aldo ; Matteucci, Fabrizio ; Galli, Luca ; Cocuzza, Paola ; Ferrazza, Patrizia ; Coraggio, Gabriele ; Pasqualetti, Giuseppe ; Derosa, Lisa ; Sollini, Martina ; Mannelli, Lorenzo ; Ortori, Simona ; Monzani, Fabio ; Ricci, Sergio ; Greco, Carlo ; Fabrini, Maria Grazia ; Erba, Paola Anna. / [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients : Preliminary results. In: Radiation Oncology. 2016 ; Vol. 11, No. 1.
@article{e936726ed096448cb35365a90012ff0e,
title = "[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: Preliminary results",
abstract = "Background: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). Methods: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [18F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [18F]FMCHPET/CT. Results: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3-40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20-62.14 months). No grade 3 or 4 toxicity was recorded. Conclusions: Repeated salvage [18F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa.",
keywords = "Choline PET/CT, Oligometastatic patients, Recurrent prostate cancer, Stereotactic body radiotherapy",
author = "Francesco Pasqualetti and Marco Panichi and Aldo Sainato and Fabrizio Matteucci and Luca Galli and Paola Cocuzza and Patrizia Ferrazza and Gabriele Coraggio and Giuseppe Pasqualetti and Lisa Derosa and Martina Sollini and Lorenzo Mannelli and Simona Ortori and Fabio Monzani and Sergio Ricci and Carlo Greco and Fabrini, {Maria Grazia} and Erba, {Paola Anna}",
year = "2016",
month = "1",
day = "22",
doi = "10.1186/s13014-016-0586-x",
language = "English",
volume = "11",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients

T2 - Preliminary results

AU - Pasqualetti, Francesco

AU - Panichi, Marco

AU - Sainato, Aldo

AU - Matteucci, Fabrizio

AU - Galli, Luca

AU - Cocuzza, Paola

AU - Ferrazza, Patrizia

AU - Coraggio, Gabriele

AU - Pasqualetti, Giuseppe

AU - Derosa, Lisa

AU - Sollini, Martina

AU - Mannelli, Lorenzo

AU - Ortori, Simona

AU - Monzani, Fabio

AU - Ricci, Sergio

AU - Greco, Carlo

AU - Fabrini, Maria Grazia

AU - Erba, Paola Anna

PY - 2016/1/22

Y1 - 2016/1/22

N2 - Background: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). Methods: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [18F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [18F]FMCHPET/CT. Results: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3-40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20-62.14 months). No grade 3 or 4 toxicity was recorded. Conclusions: Repeated salvage [18F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa.

AB - Background: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). Methods: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [18F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [18F]FMCHPET/CT. Results: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3-40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20-62.14 months). No grade 3 or 4 toxicity was recorded. Conclusions: Repeated salvage [18F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa.

KW - Choline PET/CT

KW - Oligometastatic patients

KW - Recurrent prostate cancer

KW - Stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84959131193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959131193&partnerID=8YFLogxK

U2 - 10.1186/s13014-016-0586-x

DO - 10.1186/s13014-016-0586-x

M3 - Article

AN - SCOPUS:84959131193

VL - 11

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 9

ER -